Therapy-related acute myeloid leukemia and myelodysplastic syndrome among refractory germ cell tumor patients

International Journal of Urology : Official Journal of the Japanese Urological Association
Yuta InoueOsamu Ukimura

Abstract

To analyze cases of therapy-related acute myeloid leukemia and myelodysplastic syndrome diagnosed after chemotherapy for refractory testicular and extragonadal germ cell tumor in our experience. A total of 171 consecutive patients who were diagnosed and treated as refractory germ cell tumor and had records of detailed chemotherapy doses between April 1998 and December 2015 were retrospectively reviewed. Four testicular tumor patients (4/171, 2.3%) developed therapy-related acute myeloid leukemia and myelodysplastic syndrome. Three of them were affected after complete remission of the primary testicular tumor. A median time interval from a start of chemotherapy to a secondary tumor development was 6.8 years (range 3.7-11.5 years). The median total dose of etoposide, ifosfamide, cisplatin and nedaplatin were 3640 mg/m2 (range 2906-4000 mg/m2 ), 42.7 g (range 19.5-54.0 g), 1100 mg/m2 (range 600-1500 mg/m2 ) and 500 mg/m2 (range 300-1600 mg/m2 ), respectively. Etoposide had the only significant relationship between a cumulative dose and leukemogenesis in univariate analysis (P < 0.05). One patient had complete remission, but the other three patients died. The present findings show that refractory germ cell tumor patients have an in...Continue Reading

References

Oct 21, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C KollmannsbergerC Bokemeyer
Feb 4, 1999·The New England Journal of Medicine·L B TravisM Stovall
Jul 25, 2000·Journal of the National Cancer Institute·L B TravisE Gilbert
Apr 1, 2006·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Merel R van DijkJ Dik F Habbema
Nov 11, 2006·International Journal of Cancer. Journal International Du Cancer·Lorenzo RichiardiPaul Brennan
May 16, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Valentina NardiRobert P Hasserjian
Aug 2, 2012·International Journal of Environmental Research and Public Health·Sachiko Ezoe
Sep 26, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hege S HaugnesSophie D Fosså

❮ Previous
Next ❯

Citations

Oct 1, 2018·International Journal of Urology : Official Journal of the Japanese Urological Association·Toshiaki Tanaka, Naoya Masumori
Jun 6, 2018·International Journal of Urology : Official Journal of the Japanese Urological Association·Takeshi Kishida
Nov 21, 2020·International Journal of Molecular Sciences·Luisa GesualdiAngela Catizone

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.